Work

Abstract CT117: PROCEADE PanTumor: A Phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct117

Authors: Zev A. Wainberg, Benjamin Besse, Athanasios Pallis, Christina Habermehl, Ken Kato

Institutions: University of California, Los Angeles, UCLA Medical Center, Los Angeles Medical Center, Institut Gustave Roussy, Fondation Gustave Roussy, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), National Cancer Centre Japan

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822330

Cites:

Cited by: 2

Related to: 10